Table 1.
Clinicopathological classification of primary PDAC by HER-2 expression characteristics.
| HER-2 | |||||||
|---|---|---|---|---|---|---|---|
| Score 0 | Score 1 | ||||||
| n | % | n | % | n | % | P value | |
| Age | |||||||
| <60 | 16 | 23.5 | 13 | 81.3 | 38 | 73.1 | .382 |
| ≥60 | 52 | 76.5 | 3 | 18.8 | 14 | 26.9 | |
| Gender | |||||||
| Male | 51 | 75.0 | 39 | 76.5 | 12 | 70.6 | .425 |
| Female | 17 | 25.0 | 12 | 23.5 | 5 | 29.4 | |
| Grade | |||||||
| G1 | 31 | 45.6 | 21 | 41.2 | 10 | 58.8 | .232 |
| G2 | 31 | 45.6 | 25 | 49.0 | 6 | 35.3 | |
| G3 | 6 | 8.8 | 5 | 9.8 | 1 | 5.9 | |
| Localization | |||||||
| Head | 51 | 75.0 | 36 | 70.6 | 15 | 88.2 | .092 |
| Body | 10 | 14.7 | 8 | 15.7 | 2 | 11.8 | |
| Tail | 7 | 1.3 | 7 | 13.7 | 0 | 0.0 | |
| Tumor stage | |||||||
| 1B | 5 | 7.3 | 3 | 5.9 | 2 | 11.8 | .482 |
| 1C | 17 | 25.0 | 14 | 27.5 | 3 | 17.6 | |
| 2 | 24 | 35.3 | 19 | 37.3 | 5 | 29.4 | |
| 3 | 22 | 32.4 | 15 | 29.4 | 7 | 41.2 | |
| Node stage | |||||||
| 0 | 27 | 39.7 | 22 | 43.1 | 5 | 29.4 | .326 |
| 1 | 25 | 36.8 | 18 | 35.3 | 7 | 41.2 | |
| 2 | 16 | 23.5 | 11 | 21.6 | 5 | 29.4 | |
| Clinical stage | |||||||
| IA | 13 | 19.1 | 10 | 19.6 | 3 | 17.6 | .388 |
| IB | 9 | 13.2 | 8 | 15.7 | 1 | 5.9 | |
| IIA | 5 | 7.4 | 4 | 7.8 | 1 | 5.9 | |
| IIB | 25 | 36.8 | 18 | 35.3 | 7 | 41.2 | |
| III | 16 | 23.5 | 11 | 21.6 | 5 | 29.4 | |
| PNI | |||||||
| Yes | 48 | 70.6 | 36 | 70.6 | 12 | 70.6 | .628 |
| No | 20 | 29.4 | 15 | 29.4 | 5 | 29.4 | |
| LVI | |||||||
| Yes | 39 | 57.4 | 29 | 56.9 | 10 | 58.8 | .559 |
| No | 29 | 42.6 | 22 | 43.1 | 7 | 41.2 | |
| Necrosis | |||||||
| Yes | 9 | 13.2 | 9 | 17.6 | 0 | 0.0 | .062 |
| No | 59 | 86.8 | 42 | 82.4 | 17 | 100.0 | |
| Exitus | |||||||
| Yes | 52 | 76.5 | 39 | 78.0 | 13 | 86.7 | .371 |
| No | 16 | 23.5 | 11 | 22.0 | 2 | 13 | |
Since both scores 2 and 3 are not expressed, they are not listed in the table.
HER-2 = human epidermal growth factor receptor 2, LVI = lymphovascular invasion, PDAC = pancreatic ductal adenocarcinoma, PNI = perineural invasion.